Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

Asia Pac IPO & Placement Research, China biotech

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Transcenta Holding / Equity Capital Markets

Transcenta, formerly Mabspace, is a global clinical stage biopharmaceutical company. It is looking to raise up to USD 200m via a Hong Kong listing.  In this note, we look at two drug candidates, the next generation PD-L1 MSB2311, and the Claudin 18.2 antibody, TS001. MSB2311 features PH-dependent binding property that can result in recycling of the antibody. TS001 improves the binding property and hence increases the addressable market vs the benchmark zolbetuximab. We think the company's products are differentiated though both PD-1/PD-L1, and the Claudin 18.2 class of drugs are intensely contested. The company has a strong management team with relevant experience of R&amp;D. It also has pre-IPO investors with four rounds of capital raising pre-IPO.

Transcenta, formerly Mabspace, is a global clinical stage biopharmaceutical company. It is looking to raise up to USD 200m via a Hong Kong listing.  In this note, we look at two drug candidates, the next generation PD-L1 MSB2311, and the Claudin 18.2 antibody, TS001. MSB2311 features PH-dependent binding property that can result in recycling of the antibody. TS001 improves the binding property and hence increases the addressable market vs the benchmark zolbetuximab. We think the company's products are differentiated though both PD-1/PD-L1, and the Claudin 18.2 class of drugs are intensely contested. The company has a strong management team with relevant experience of R&amp;D. It also has pre-IPO investors with four rounds of capital raising pre-IPO. 

Transcenta (创胜) Pre-IPO: Buy the Experienced Team

China

Transcenta Holding Limited operates as a global biotherapeutics company. The Company develops therapeutic antibody molecules for oncology and selected non-oncology indications including bone and kidney disorders. Transcenta Holding provides services in China.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Transcenta Holding (6628 HK)

Transcenta (创胜) Pre-IPO: Buy the Experienced Team

Formerly Mabspace, we think Transcenta has an experienced team with with innovative product though the immediate addressable market is not huge.

Ke Yan, CFA, FRM

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)